Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

ALVO vs TEVA vs VTRS vs PRGO vs MCK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ALVO
Alvotech

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • IS
Market Cap$999M
5Y Perf.-61.0%
TEVA
Teva Pharmaceutical Industries Limited

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IL
Market Cap$41.93B
5Y Perf.+378.9%
VTRS
Viatris Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$20.25B
5Y Perf.+66.1%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.61B
5Y Perf.-71.1%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+130.6%

ALVO vs TEVA vs VTRS vs PRGO vs MCK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ALVO logoALVO
TEVA logoTEVA
VTRS logoVTRS
PRGO logoPRGO
MCK logoMCK
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericMedical - Distribution
Market Cap$999M$41.93B$20.25B$1.61B$92.15B
Revenue (TTM)$586M$17.35B$14.56B$4.18B$403.43B
Net Income (TTM)$28M$1.56B$-296M$-1.82B$4.76B
Gross Margin59.8%52.1%34.4%34.2%3.6%
Operating Margin13.3%13.2%1.0%-4.1%1.5%
Forward P/E100.9x14.5x7.1x5.6x19.3x
Total Debt$1.45B$17.38B$14.70B$3.97B$7.39B
Cash & Equiv.$172M$3.56B$1.35B$532M$5.69B

ALVO vs TEVA vs VTRS vs PRGO vs MCKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ALVO
TEVA
VTRS
PRGO
MCK
StockJun 22May 26Return
Alvotech (ALVO)10039.0-61.0%
Teva Pharmaceutical… (TEVA)100478.9+378.9%
Viatris Inc. (VTRS)100166.1+66.1%
Perrigo Company plc (PRGO)10028.9-71.1%
McKesson Corporation (MCK)100230.6+130.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: ALVO vs TEVA vs VTRS vs PRGO vs MCK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: PRGO and MCK are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. McKesson Corporation is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. ALVO, TEVA, and VTRS also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
ALVO
Alvotech
The Growth Play

ALVO ranks third and is worth considering specifically for growth exposure.

  • Rev growth 19.7%, EPS growth 111.5%, 3Y rev CAGR 91.9%
  • 19.7% revenue growth vs VTRS's -3.0%
Best for: growth exposure
TEVA
Teva Pharmaceutical Industries Limited
The Quality Compounder

TEVA is the clearest fit if your priority is quality.

  • 9.0% margin vs PRGO's -43.5%
Best for: quality
VTRS
Viatris Inc.
The Defensive Pick

VTRS is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 0.99, Low D/E 99.9%, current ratio 1.30x
  • +107.8% vs ALVO's -59.7%
Best for: sleep-well-at-night
PRGO
Perrigo Company plc
The Defensive Pick

PRGO has the current edge in this matchup, primarily because of its strength in defensive.

  • Beta 1.18, yield 9.8%, current ratio 2.76x
  • Lower P/E (5.6x vs 19.3x)
  • 9.8% yield, 10-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
Best for: defensive
MCK
McKesson Corporation
The Income Pick

MCK is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.

  • Dividend streak 17 yrs, beta 0.04, yield 0.4%
  • 348.1% 10Y total return vs TEVA's -28.3%
  • Beta 0.04 vs PRGO's 1.18
  • 5.7% ROA vs PRGO's -19.8%, ROIC 5.4% vs 3.7%
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthALVO logoALVO19.7% revenue growth vs VTRS's -3.0%
ValuePRGO logoPRGOLower P/E (5.6x vs 19.3x)
Quality / MarginsTEVA logoTEVA9.0% margin vs PRGO's -43.5%
Stability / SafetyMCK logoMCKBeta 0.04 vs PRGO's 1.18
DividendsPRGO logoPRGO9.8% yield, 10-year raise streak, vs MCK's 0.4%, (2 stocks pay no dividend)
Momentum (1Y)VTRS logoVTRS+107.8% vs ALVO's -59.7%
Efficiency (ROA)MCK logoMCK5.7% ROA vs PRGO's -19.8%, ROIC 5.4% vs 3.7%

ALVO vs TEVA vs VTRS vs PRGO vs MCK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ALVOAlvotech
FY 2023
Humira
100.0%$12.2B
TEVATeva Pharmaceutical Industries Limited
FY 2025
Product
84.6%$14.6B
Distribution Service
9.0%$1.6B
License
3.9%$678M
Product and Service, Other
2.5%$423M
VTRSViatris Inc.
FY 2025
Brands
64.4%$9.2B
Generics
35.6%$5.1B
PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B

ALVO vs TEVA vs VTRS vs PRGO vs MCK — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALVOLAGGINGVTRS

Income & Cash Flow (Last 12 Months)

ALVO leads this category, winning 3 of 6 comparable metrics.

MCK is the larger business by revenue, generating $403.4B annually — 688.1x ALVO's $586M. TEVA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, ALVO holds the edge at +10.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricALVO logoALVOAlvotechTEVA logoTEVATeva Pharmaceutic…VTRS logoVTRSViatris Inc.PRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…
RevenueTrailing 12 months$586M$17.3B$14.6B$4.2B$403.4B
EBITDAEarnings before interest/tax$78M$3.3B$2.3B$58M$6.8B
Net IncomeAfter-tax profit$28M$1.6B-$296M-$1.8B$4.8B
Free Cash FlowCash after capex-$115M$1.2B$1.7B$108M$6.0B
Gross MarginGross profit ÷ Revenue+59.8%+52.1%+34.4%+34.2%+3.6%
Operating MarginEBIT ÷ Revenue+13.3%+13.2%+1.0%-4.1%+1.5%
Net MarginNet income ÷ Revenue+4.8%+9.0%-2.0%-43.5%+1.2%
FCF MarginFCF ÷ Revenue-19.6%+6.8%+11.7%+2.6%+1.5%
Rev. Growth (YoY)Latest quarter vs prior year+10.0%+2.3%+8.1%-7.2%+6.0%
EPS Growth (YoY)Latest quarter vs prior year-95.5%+72.2%+105.9%-56.4%+37.0%
ALVO leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

PRGO leads this category, winning 3 of 6 comparable metrics.

At 29.2x trailing earnings, MCK trades at a 9% valuation discount to ALVO's 32.0x P/E. On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than VTRS's 248.5x.

MetricALVO logoALVOAlvotechTEVA logoTEVATeva Pharmaceutic…VTRS logoVTRSViatris Inc.PRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…
Market CapShares × price$999M$41.9B$20.2B$1.6B$92.1B
Enterprise ValueMkt cap + debt − cash$2.3B$55.8B$33.6B$5.1B$93.8B
Trailing P/EPrice ÷ TTM EPS32.00x30.01x-5.80x-1.14x29.25x
Forward P/EPrice ÷ next-FY EPS est.100.95x14.55x7.12x5.56x19.28x
PEG RatioP/E ÷ EPS growth rate0.75x
EV / EBITDAEnterprise value multiple19.61x17.65x248.54x7.42x18.74x
Price / SalesMarket cap ÷ Revenue1.70x2.43x1.42x0.38x0.26x
Price / BookPrice ÷ Book value/share5.34x1.38x0.55x
Price / FCFMarket cap ÷ FCF36.52x10.45x11.12x17.63x
PRGO leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 5 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-51 for PRGO. VTRS carries lower financial leverage with a 1.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to TEVA's 2.20x. On the Piotroski fundamental quality scale (0–9), TEVA scores 8/9 vs ALVO's 3/9, reflecting strong financial health.

MetricALVO logoALVOAlvotechTEVA logoTEVATeva Pharmaceutic…VTRS logoVTRSViatris Inc.PRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…
ROE (TTM)Return on equity+20.7%-2.0%-50.7%+3.0%
ROA (TTM)Return on assets+2.0%+3.9%-0.8%-19.8%+5.7%
ROICReturn on invested capital+6.8%+7.7%-6.6%+3.7%+5.4%
ROCEReturn on capital employed+7.1%+8.0%-8.1%+4.3%+30.5%
Piotroski ScoreFundamental quality 0–938446
Debt / EquityFinancial leverage2.20x1.00x1.35x
Net DebtTotal debt minus cash$1.3B$13.8B$13.4B$3.4B$1.7B
Cash & Equiv.Liquid assets$172M$3.6B$1.3B$532M$5.7B
Total DebtShort + long-term debt$1.4B$17.4B$14.7B$4.0B$7.4B
Interest CoverageEBIT ÷ Interest expense0.52x2.51x-0.51x-7.20x33.79x
MCK leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — TEVA and VTRS and MCK each lead in 2 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $2,860 for ALVO. Over the past 12 months, VTRS leads with a +107.8% total return vs ALVO's -59.7%. The 3-year compound annual growth rate (CAGR) favors TEVA at 58.4% vs ALVO's -30.4% — a key indicator of consistent wealth creation.

MetricALVO logoALVOAlvotechTEVA logoTEVATeva Pharmaceutic…VTRS logoVTRSViatris Inc.PRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…
YTD ReturnYear-to-date-36.0%+16.3%+40.5%-13.5%-8.5%
1-Year ReturnPast 12 months-59.7%+104.6%+107.8%-51.2%+4.6%
3-Year ReturnCumulative with dividends-66.3%+297.5%+91.8%-58.1%+106.4%
5-Year ReturnCumulative with dividends-71.4%+246.2%+40.3%-60.1%+286.9%
10-Year ReturnCumulative with dividends-71.4%-28.3%-51.5%-77.7%+348.1%
CAGR (3Y)Annualised 3-year return-30.4%+58.4%+24.2%-25.2%+27.3%
Evenly matched — TEVA and VTRS and MCK each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — VTRS and MCK each lead in 1 of 2 comparable metrics.

MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than PRGO's 1.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VTRS currently trades 99.7% from its 52-week high vs ALVO's 27.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricALVO logoALVOAlvotechTEVA logoTEVATeva Pharmaceutic…VTRS logoVTRSViatris Inc.PRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…
Beta (5Y)Sensitivity to S&P 5001.11x1.13x0.99x1.18x0.04x
52-Week HighHighest price in past year$11.85$37.35$17.45$28.44$999.00
52-Week LowLowest price in past year$3.03$14.99$8.19$9.23$637.00
% of 52W HighCurrent price vs 52-week peak+27.0%+96.4%+99.7%+41.2%+75.3%
RSI (14)Momentum oscillator 0–10051.573.575.760.916.2
Avg Volume (50D)Average daily shares traded510K6.6M10.6M3.4M757K
Evenly matched — VTRS and MCK each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — PRGO and MCK each lead in 1 of 2 comparable metrics.

Analyst consensus: ALVO as "Buy", TEVA as "Buy", VTRS as "Hold", PRGO as "Hold", MCK as "Buy". Consensus price targets imply 168.7% upside for ALVO (target: $9) vs -12.3% for VTRS (target: $15). For income investors, PRGO offers the higher dividend yield at 9.81% vs MCK's 0.36%.

MetricALVO logoALVOAlvotechTEVA logoTEVATeva Pharmaceutic…VTRS logoVTRSViatris Inc.PRGO logoPRGOPerrigo Company p…MCK logoMCKMcKesson Corporat…
Analyst RatingConsensus buy/hold/sellBuyBuyHoldHoldBuy
Price TargetConsensus 12-month target$8.60$39.00$15.25$20.00$1006.50
# AnalystsCovering analysts546123631
Dividend YieldAnnual dividend ÷ price+2.8%+9.8%+0.4%
Dividend StreakConsecutive years of raises101017
Dividend / ShareAnnual DPS$0.48$1.15$2.69
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+2.5%0.0%+3.4%
Evenly matched — PRGO and MCK each lead in 1 of 2 comparable metrics.
Key Takeaway

ALVO leads in 1 of 6 categories (Income & Cash Flow). PRGO leads in 1 (Valuation Metrics). 3 tied.

Best OverallAlvotech (ALVO)Leads 1 of 6 categories
Loading custom metrics...

ALVO vs TEVA vs VTRS vs PRGO vs MCK: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ALVO or TEVA or VTRS or PRGO or MCK a better buy right now?

For growth investors, Alvotech (ALVO) is the stronger pick with 19.

7% revenue growth year-over-year, versus -3. 0% for Viatris Inc. (VTRS). McKesson Corporation (MCK) offers the better valuation at 29. 2x trailing P/E (19. 3x forward), making it the more compelling value choice. Analysts rate Alvotech (ALVO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ALVO or TEVA or VTRS or PRGO or MCK?

On trailing P/E, McKesson Corporation (MCK) is the cheapest at 29.

2x versus Alvotech at 32. 0x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — ALVO or TEVA or VTRS or PRGO or MCK?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -71. 4% for Alvotech (ALVO). Over 10 years, the gap is even starker: MCK returned +348. 1% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ALVO or TEVA or VTRS or PRGO or MCK?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus Perrigo Company plc's 1. 18β — meaning PRGO is approximately 2641% more volatile than MCK relative to the S&P 500. On balance sheet safety, Viatris Inc. (VTRS) carries a lower debt/equity ratio of 100% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.

05

Which is growing faster — ALVO or TEVA or VTRS or PRGO or MCK?

By revenue growth (latest reported year), Alvotech (ALVO) is pulling ahead at 19.

7% versus -3. 0% for Viatris Inc. (VTRS). On earnings-per-share growth, the picture is similar: Teva Pharmaceutical Industries Limited grew EPS 182. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, ALVO leads at 91. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ALVO or TEVA or VTRS or PRGO or MCK?

Teva Pharmaceutical Industries Limited (TEVA) is the more profitable company, earning 8.

2% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 8. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALVO leads at 13. 3% versus -18. 6% for VTRS. At the gross margin level — before operating expenses — ALVO leads at 59. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ALVO or TEVA or VTRS or PRGO or MCK more undervalued right now?

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 100. 9x for Alvotech — 95. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALVO: 168. 7% to $8. 60.

08

Which pays a better dividend — ALVO or TEVA or VTRS or PRGO or MCK?

In this comparison, PRGO (9.

8% yield), VTRS (2. 8% yield), MCK (0. 4% yield) pay a dividend. ALVO, TEVA do not pay a meaningful dividend and should not be held primarily for income.

09

Is ALVO or TEVA or VTRS or PRGO or MCK better for a retirement portfolio?

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), +348. 1% 10Y return). Both have compounded well over 10 years (MCK: +348. 1%, ALVO: -71. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ALVO and TEVA and VTRS and PRGO and MCK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ALVO is a small-cap high-growth stock; TEVA is a mid-cap quality compounder stock; VTRS is a mid-cap quality compounder stock; PRGO is a small-cap income-oriented stock; MCK is a mid-cap high-growth stock. VTRS, PRGO pay a dividend while ALVO, TEVA, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ALVO

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 35%
Run This Screen
Stocks Like

TEVA

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

VTRS

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 20%
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform ALVO and TEVA and VTRS and PRGO and MCK on the metrics below

Revenue Growth>
%
(ALVO: 10.0% · TEVA: 2.3%)
Net Margin>
%
(ALVO: 4.8% · TEVA: 9.0%)
P/E Ratio<
x
(ALVO: 32.0x · TEVA: 30.0x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.